Loading...

MRSN MERSANA THERAPEUTICS INC Product Launches 8-K Filing

MRSN

MRSN

MERSANA THERAPEUTICS INC

(MRSN)

2025 8-K

Show Summary

Summary

Loan Defaults (Secured, Uns...

Reverse Stock Split

New Product Launches

Financial Statements

Management Changes

Financial Results

Corporate Update

Corporate Update

Clinical Trial Update

Stock Exchange Agreement

Financial Results

Financial Results

Annual Meeting of Stockholders

Earnings Report

Sales Agreement

Financial Results Announcement

Disclosure and Business Upd...

Termination of Agreement

Financial Results Announcement

FDA Clinical Hold Lifted

Financial Results Announcement

Financial Results and Restr...

Clinical Hold Announcement

Amendment and Annual Meeting

Earnings Reports

Bylaws Amendments

Loan Agreement Amendment

Financial Results Announcement

Presentation and Clinical T...

Disclosure and Other Events

Financial Update

External Links:

On June 2, 2025, Mersana Therapeutics shared positive interim data from its Phase 1 trial of Emi-Le for treating various cancers, showing a 31% confirmed objective response rate across all tumors, particularly noting a 56% response rate in adenoid cystic carcinoma (ACC-1) patients.

AI Assistant

MERSANA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.